Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2026)
Camp4 Therapeutics' (CAMP) quarterly Cash from Financing Activities came in at $57000.0 in Q1 2026, up 137.75% year-on-year from $23974.9 in Q1 2025, and down 99.8% quarter-over-quarter from $28.6 million in Q4 2025.
Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $57000.0 for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $57000.0, up 137.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.1 million (up 6.11% YoY), and the FY2025 annual result was $75.9 million, up 5.9% from the prior year.
- Cash from Financing Activities came in at $57000.0 for Q1 2026 at Camp4 Therapeutics, down from $28.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $73.1 million in Q4 2024 to a low of -$812000.0 in Q2 2024.
- The 4-year median for Cash from Financing Activities is -$3000.0 (2023), against an average of $14.8 million.
- Across the five-year window, Cash from Financing Activities surged 116071.43% in 2024 and slumped 60.88% in 2025, its largest moves.
- Camp4 Therapeutics' Cash from Financing Activities stood at -$63000.0 in 2023, then soared by 116071.43% to $73.1 million in 2024, then plunged by 60.88% to $28.6 million in 2025, then slumped by 99.8% to $57000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $57000.0 (Q1 2026), $28.6 million (Q4 2025), and $47.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Camp4 Therapeutics | 245.02 Mn | 245.02 Mn | - | 57,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 28.59 Mn |
| Dec 31, 2025 | 28.59 Mn |
| Sep 30, 2025 | 47.38 Mn |
| Sep 30, 2025 | 47.38 Mn |
| Jun 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Dec 31, 2024 | 73.06 Mn |
| Dec 31, 2024 | 73.06 Mn |
| Sep 30, 2024 | -386,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Jun 30, 2024 | -812,000.00 |
| Jun 30, 2024 | -812,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Dec 31, 2023 | -63,000.00 |
| Dec 31, 2023 | -63,000.00 |